George Magrath - 24 Mar 2025 Form 4 Insider Report for Opus Genetics, Inc. (IRD)

Role: Chief Executive Officer, Director
Signature: /s/ Sharon Goldbach, by Power of Attorney
Issuer symbol: IRD
Transactions as of: 24 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 26 Mar 2025, 16:10:20 UTC
Previous filing: 17 Mar 2025
Next filing: 05 Nov 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IRD	Common Stock	Award		+392,157	+42%		1,322,004	24 Mar 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IRD	Warrants (right to buy)	Award		+392,157			392,157	24 Mar 2025	Common Stock	392,157	$1.15	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275.
F2	These warrants are immediately exercisable and may be called by the Issuer at any time starting with 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's common stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day.

Content

Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275.

These warrants are immediately exercisable and may be called by the Issuer at any time starting with 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's common stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day.